Should I buy or sell AVROBIO stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVRO, but not buy additional shares or sell existing shares. View AVRO analyst ratings or view top-rated stocks .

What is AVROBIO's stock price target for 2024?

2 brokers have issued 12 month price objectives for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts .

How have AVRO shares performed in 2024?

AVROBIO's stock was trading at $1.36 on January 1st, 2024. Since then, AVRO stock has decreased by 10.3% and is now trading at $1.22. View the best growth stocks for 2024 here .

Are investors shorting AVROBIO?

AVROBIO saw a increase in short interest in March. As of March 31st, there was short interest totaling 143,200 shares, an increase of 14.6% from the March 15th total of 125,000 shares. Based on an average daily volume of 299,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.4% of the shares of the stock are sold short. View AVROBIO's Short Interest .

When is AVROBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AVRO earnings forecast .

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its earnings results on Thursday, November, 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75).

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE) , ImmunoGen (imgn) , Aduro Biotech (ADRO) , Aldeyra Therapeutics (ALDX) , Amarin (AMRN) , Biohaven (BHVN) , Nabriva Therapeutics (NBRV) , Selecta Biosciences (SELB) , VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS) .

When did AVROBIO IPO?

AVROBIO (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

How do I buy shares of AVROBIO?

Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVRO

AVROBIO (AVRO) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free AVRO Stock Alerts

$1.22

-0.04 (-3.17%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.20
▼
$1.27
50-Day Range: $1.22
▼
$1.34
52-Week Range: $0.57
▼
$1.70

Volume: 203,387 shs
Average Volume: 284,085 shs
Market Capitalization: $54.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Get AVROBIO alerts:

AVROBIO MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 63.9% Upside
$2.00 Price Target
Short Interest: Healthy
0.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.58 to ($0.48) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars

Medical Sector

598th out of 913 stocks

Biological Products, Except Diagnostic Industry

88th out of 137 stocks

3.0

Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
AVROBIO has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.37% of the float of AVROBIO has been sold short.
Short Interest Ratio / Days to Cover
AVROBIO has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AVROBIO has recently increased by 14.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVRO.

1.9

News and Social Media Coverage

News Sentiment
AVROBIO has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for AVROBIO this week, compared to 1 article on an average week.
Search Interest
4 people have searched for AVRO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.20% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
62.63% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to decrease in the coming year, from $0.58 to ($0.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -12.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -12.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About AVROBIO Stock (NASDAQ:AVRO)

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVRO Stock News Headlines

March 26, 2024 | wsj.com

AVROBIO Inc.

February 23, 2024 | ca.finance.yahoo.com

AVRO Apr 2024 2.500 call

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

February 18, 2024 | finance.yahoo.com

AVRO May 2024 2.500 call

February 14, 2024 | businesswire.com

AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

January 31, 2024 | stockhouse.com

Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic

January 31, 2024 | bizjournals.com

Five things: Vertex's new drug, a reverse merger, and how are you doing?

January 31, 2024 | msn.com

Avrobio Inc Announces Executive Team Changes and Appointments

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

January 30, 2024 | bizjournals.com

Avrobio to take Watertown biotech public via reverse merger

January 30, 2024 | stockhouse.com

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL

January 30, 2024 | msn.com

Avrobio to buy 100% equity interests of Tectonic Therapeutic

January 30, 2024 | marketwatch.com

Avrobio Shares Dive 17% After Tectonic Therapeutic Deal

January 30, 2024 | finance.yahoo.com

AVROBIO and Tectonic Therapeutic Announce Merger

December 20, 2023 | benzinga.com

Avrobio Stock (NASDAQ:AVRO), Analyst Ratings, Price Targets, Predictions

December 19, 2023 | msn.com

Mizuho Downgrades AVROBIO (AVRO)

December 19, 2023 | benzinga.com

Avrobio Stock (NASDAQ:AVRO) Dividends: History, Yield and Dates

December 18, 2023 | realmoney.thestreet.com

Avrobio just downgraded at Mizuho, here's why

November 14, 2023 | morningstar.com

Avrobio Inc AVRO

November 14, 2023 | markets.businessinsider.com

Potential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for Avrobio

November 8, 2023 | finance.yahoo.com

Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?

October 6, 2023 | finance.yahoo.com

Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?

October 5, 2023 | msn.com

AvroBio (AVRO) Price Target Increased by 12.82% to 3.74

September 25, 2023 | ca.finance.yahoo.com

AVROBIO, Inc. (AVRO)

September 11, 2023 | benzinga.com

Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer

August 12, 2023 | msn.com

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

August 11, 2023 | markets.businessinsider.com

Avrobio (AVRO) Gets a Buy from Barclays

See More Headlines

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AVRO
CUSIP: N/A
CIK: 1681087
Web: www.avrobio.com
Phone: (617) 914-8420
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +63.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 2.10
P/E Growth: N/A
Net Income: $12.16 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -74.86%
Return on Assets: -65.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.78
Quick Ratio: 15.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.28 per share
Price / Cash Flow: 4.40
Book Value: $2.13 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 44,860,000
Free Float: 40,734,000
Market Cap: $54.73 million
Optionable: Optionable
Beta: 1.22

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Erik John Ostrowski M.B.A. (Age 52)
President, Interim CEO, CFO & Treasurer
Comp: $1.25M
Dr. Azadeh Golipour Ph.D. (Age 44)
Chief Technology Officer
Comp: $1.01M
Dr. Essra Ridha FFPM (Age 41)
M.D., Chief Medical Officer
Comp: $1.12M
Mr. Jeffrey Medin Ph.D.
Scientific Founder
Mr. Steven N. Avruch J.D. (Age 62)
Chief Legal Officer & Secretary
Comp: $506.68k
Mr. Scott Gottesman
Vice President of Human Resource
Ms. Kirsten Dupuis
Chief of Staff

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVRO, but not buy additional shares or sell existing shares.
View AVRO analyst ratings or view top-rated stocks.
What is AVROBIO's stock price target for 2024?: 2 brokers have issued 12 month price objectives for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price.
View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts.
How have AVRO shares performed in 2024?: AVROBIO's stock was trading at $1.36 on January 1st, 2024. Since then, AVRO stock has decreased by 10.3% and is now trading at $1.22.
View the best growth stocks for 2024 here.
Are investors shorting AVROBIO?: AVROBIO saw a increase in short interest in March. As of March 31st, there was short interest totaling 143,200 shares, an increase of 14.6% from the March 15th total of 125,000 shares. Based on an average daily volume of 299,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.4% of the shares of the stock are sold short.
View AVROBIO's Short Interest.
When is AVROBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AVRO earnings forecast.

How were AVROBIO's earnings last quarter?: AVROBIO, Inc. (NASDAQ:AVRO) released its earnings results on Thursday, November, 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75).
What other stocks do shareholders of AVROBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).
When did AVROBIO IPO?: AVROBIO (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.
How do I buy shares of AVROBIO?: Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVRO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AVROBIO (AVRO) Stock Price, News & Analysis

AVROBIO MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AVROBIO Stock (NASDAQ:AVRO)

AVRO Stock Price History

AVRO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

AVRO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™